Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised full-year 2026 revenue guidance to $192-196 million and reported improved adjusted EBITDA from continuing operations.

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.

Cryoport announced the launch of the MVE Fusion® 800 Series, a self-sustaining cryogenic freezer that eliminates the need for continuous liquid nitrogen supply. The compact system, recognized with the ISBER Outstanding New Product Award, is designed for space-constrained environments like medical research facilities, hospitals, and biorepositories, maintaining temperatures at or below -150°C.

Cryoport Systems has become the first global supply chain solutions company to achieve ISO 21973 certification, demonstrating its leadership in ensuring safe and traceable transportation of cell and gene therapies.

Cryoport Systems has launched a new 55,000-square-foot global supply chain center near Paris, France, expanding its network to support complex life sciences supply chain needs, including biologistics and bioservices.

The global clinical trial biorepository and archiving solutions market is projected to grow from USD 4.76 billion in 2025 to USD 9.69 billion by 2034, with a CAGR of 8.21%. North America dominates the market, while Asia Pacific is expected to experience the fastest growth, driven by advancements in biobanking technologies and increasing demand for personalized medicine.

Cryoport CEO Jerrell Shelton exercised and sold 16,344 shares at $7.06 per share, retaining 928,763 shares. The company continues to face financial challenges with recent revenue drops and ongoing losses.

Cryoport, a global provider of supply chain solutions for the life sciences sector, will report its first quarter 2025 financial results on May 7, 2025. The company will host a conference call to discuss the results.

Cryoport and Gulf Coast Regional Blood Center have formed a strategic alliance to enhance the availability of high-quality, cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment. The partnership coincides with the grand opening of Cryoport's new state-of-the-art IntegriCell™ facility in Houston, Texas.

TMRW Life Sciences and Cryoport Systems have formed a strategic partnership to provide fertility clinics with comprehensive solutions for secure specimen management and transport. The partnership combines TMRW's fertility technology and Cryoport's expertise in temperature-controlled logistics to ensure the highest standards of safety, security, and quality control.

SK pharmteco, a global CDMO, and Cryoport, a leader in supply chain solutions for the life sciences industry, have announced a strategic collaboration to provide integrated logistics and manufacturing services for biotechnology and pharmaceutical companies.